These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31415942)

  • 1. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.
    Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L
    Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
    Agha ME; Monaghan SA; Swerdlow SH
    N Engl J Med; 2018 Oct; 379(15):1479-1481. PubMed ID: 30304659
    [No Abstract]   [Full Text] [Related]  

  • 3. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
    Gangat N; Konopleva M; Patnaik MM; Jabbour E; DiNardo C; Al-Kali A; Foran JM; Granroth GL; Olteanu H; Kadia T; Tefferi A; Pemmaraju N
    Am J Hematol; 2022 Feb; 97(2):E62-E67. PubMed ID: 34807470
    [No Abstract]   [Full Text] [Related]  

  • 5. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
    Piccini M; Loscocco GG; Gianfaldoni G; Grieco P; Palmieri G; Pilerci S; Scappini B; Bosi A
    Ann Hematol; 2020 Apr; 99(4):907-909. PubMed ID: 32030448
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
    Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
    Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
    Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 10. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
    Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
    Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
    Stephens DM
    Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
    Schwede M; Tan IT; Atibalentja DF; Dickman MM; Rieger KE; Mannis GN
    Ann Hematol; 2020 Dec; 99(12):2973-2975. PubMed ID: 32968828
    [No Abstract]   [Full Text] [Related]  

  • 17. Autoimmune hemolytic anemia, adverse event to venetoclax.
    Carriles C; Ordóñez-Fernández L; Arias-Martínez A; Menárguez-Blanc R; Rosado-María MC
    Farm Hosp; 2019 Sep; 43(5):166-167. PubMed ID: 31469630
    [No Abstract]   [Full Text] [Related]  

  • 18. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
    Eradat H
    Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.